上海科华生物工程股份有限公司 2022 年第三季度报告 证券代码：002022 证券简称：*ST科华 公告编号：2022-096 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 2.公司负责人马志超先生、主管会计工作负责人罗芳女士及会计机构负责人(会计主管人员)俞蕾女士声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 676,494,983.81 ...

上海科华生物工程股份有限公司 2022 年半年度报告全文 上海科华生物工程股份有限公司 2022 年半年度报告 2022-065 2022 年 08 月 1 上海科华生物工程股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人周琴琴、主管会计工作负责人罗芳及会计机构负责人(会计主 管人员)俞蕾声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司控股子公司西安天隆科技有限公司、苏州天隆生物科技有限公司（以 下简称"天隆公司"）管理层，违反本公司对控股子公司管理规章制度的规定， 违反天隆公司《公司章程》规定，拒绝履行天隆公司董事会做出的决议，拒绝 配合本公司聘请的立信会计师事务所（特殊普通合伙）开展 2021 年度审计工 作，公司董事会基于谨慎考虑，审议将天隆公司自 2021 年 10 月 1 日起暂不纳 入公司合并报表。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质 ...

Financial Performance - The company's operating revenue for 2021 was CNY 4,268,011,808.72, representing a 2.71% increase compared to CNY 4,155,428,846.74 in 2020[20] - The net profit attributable to shareholders for 2021 was CNY 721,016,662.06, a 6.76% increase from CNY 675,356,413.28 in 2020[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 704,501,000.58, up 6.92% from CNY 658,928,540.60 in 2020[20] - Basic earnings per share for 2021 were CNY 1.4026, an increase of 5.10% from CNY 1.3345 in 2020[20] - The diluted earnings per share for 2021 were CNY 1.3641, a 3.54% increase from CNY 1.3175 in 2020[20] - The weighted average return on equity decreased to 20.87% from 24.76% in 2020, a decline of 3.89%[20] - Total assets at the end of 2021 were CNY 5,276,579,515.63, down 11.72% from CNY 5,977,153,474.43 at the end of 2020[20] - The net cash flow from operating activities decreased by 43.29% to CNY 775,342,174.21 from CNY 1,367,198,250.32 in 2020[20] - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[124] - The company reported a net profit of 300 million RMB, reflecting a 20% increase from the previous year[124] Market and Product Development - The company’s main business includes the R&D, production, and sales of in vitro diagnostic reagents and medical testing instruments, focusing on molecular, biochemical, and immunodiagnostics[34] - The global in vitro diagnostic market exceeded $111.7 billion in 2021, with a projected CAGR of 6.1% from 2017 to 2024, indicating strong growth potential in the industry[32] - The company has over 200 diagnostic reagents and instruments, with more than 80 products certified by the EU CE mark, and has exported products to over 30 countries and regions[34] - The company launched 21 reagent products and 2 instrument products that received medical device registration certificates during the reporting period, enhancing its product portfolio[44] - The Polaris ic6000 product was successfully launched, designed for large laboratories, contributing to the company's innovation in automated biochemical and immunological analysis systems[42] - The company aims to launch three new products in the next quarter, which are anticipated to contribute an additional 100 million RMB in revenue[126] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[125] Research and Development - The company has over 100 ongoing research projects and has obtained 260 CFDA registration certificates and more than 50 invention patents[38] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[119] - Investment in R&D for new technologies increased by 25%, totaling 200 million RMB, focusing on immunological and molecular diagnostics[124] - The company will continue to invest in R&D, particularly in molecular and immunological fields, to develop new products and improve existing ones[97] Challenges and Risks - The company faces risks related to the ongoing COVID-19 pandemic, which may impact sales of diagnostic products[98] - Regulatory changes in the in vitro diagnostic industry pose a risk to the company's operations and compliance[99] - The company faces increasing challenges in the in vitro diagnostic industry due to healthcare cost control measures, which may accelerate industry concentration and require manufacturers to strengthen their marketing capabilities[101] - The company is currently involved in a significant arbitration case, with the Shanghai International Economic and Trade Arbitration Commission having formed a tribunal, but no ruling has been made yet, making the impact on profits uncertain[102] - The company's stock has been placed under delisting risk warning due to management violations at its subsidiaries, leading to an "unable to express opinion" audit report for the 2021 fiscal year[102] Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and various committees to ensure compliance with laws and regulations[107] - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management to ensure the achievement of strategic goals[109] - The company has committed to improving its information disclosure practices, ensuring timely and accurate communication with investors[110] - The company maintains complete independence from its major shareholders in terms of business operations, personnel, assets, institutions, and finance[111] - The company has established independent departments for various functions, including sales, R&D, procurement, and finance, ensuring operational independence[112] Employee and Operational Management - The total number of employees at the end of the reporting period was 1,485, with 926 in the parent company and 559 in major subsidiaries[137] - The company has a training plan that includes diverse training programs for different employee levels, aimed at enhancing organizational performance[140] - The company has established a performance-oriented compensation system that aligns employee contributions with organizational goals[139] - The company’s internal control and compliance management received positive feedback from the audit committee, indicating effective governance[136] Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 0.65 per 10 shares (including tax) to all shareholders[6] - The total distributable profit for the period was 759,082,903.41 CNY, with the cash dividend representing 100% of the profit distribution[144] - The company did not propose any stock dividends or capital reserve transfers during the reporting period[146] Financial Management and Investments - The company has established a new supply chain management structure to optimize processes and reduce costs, enhancing operational efficiency[46] - The company reported a significant decrease in investment amounting to CNY 7.14 million, a decline of 71.27% compared to the previous year's CNY 24.85 million[77] - The company raised a total of CNY 738 million through the issuance of convertible bonds, with a net amount of CNY 718.53 million after deducting issuance costs[85] Social Responsibility - A 22-member volunteer team was formed to assist in COVID-19 testing efforts, demonstrating the company's commitment to social responsibility[166]

上海科华生物工程股份有限公司 2022 年第一季度报告全文 | 证券代码：002022 | 证券简称：科华生物 | 公告编号：2022-019 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 公司 2022 年 4 月 28 日召开第八届董事会第十六次会议，审议《关于控股子公司暂时失去控制且暂不纳入合并报表范围 的议案》，因天隆公司管理层违反本公司对控股子公司管理规章制度的规定，违反天隆公司《公司章程》规定，拒绝履行天 隆公司董事会做出的决议，拒绝配合本公司聘请的立信会计师事务所（特殊普通合伙）开展 2021 年度审计工作，公司目前 已经无法取得天隆公司的财务资料，无法掌握天隆公司的实际经营情况、资产状况及面临的风险等信息，公司对天隆公司的 管理控制无法得到天隆公司管理层的执行。公司董事会基于谨慎考虑，审议将天隆公司自 2021 年 10 月 1 日起暂不纳入公司 合并报表。 上海科华生物工程股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会 ...

上海科华生物工程股份有限公司 2021 年第三季度报告 | 证券代码：002022 | 证券简称：科华生物 | 公告编号：2021-094 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 上海科华生物工程股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 1,327,832,849.51 | 19.93% | 3,727,801,760.84 | 45.19% | | 归属于上市公司股东的 | 250,039,443.94 | 19.54% | 729,089,582.16 | 81.44% | | 净利润（元） | | | | | | 归属于上市公司股东的 扣除非经常性损益的净 | 251,215,709.56 | 22.19% | 723,898,9 ...

上海科华生物工程股份有限公司 2021 年半年度报告全文 上海科华生物工程股份有限公司 2021 年半年度报告 2021-078 2021 年 08 月 1 上海科华生物工程股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人周琴琴、主管会计工作负责人罗芳及会计机构负责人(会计主管 人员)许振中声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质性承诺， 投资者及相关人士应当对此保持足够的风险认识，并应当理解计划、预测与承 诺之间的差异。 本公司请投资者认真阅读本报告，公司在本报告第三节"管理层讨论与分 析"中"十、公司面临的风险及应对措施"部分，阐述了公司未来经营可能面临的 主要风险，敬请广大投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | | 2 | | ...

Financial Performance - The company's operating revenue for 2020 was CNY 4,155,428,846.74, representing a 72.11% increase compared to CNY 2,414,471,289.30 in 2019[16] - The net profit attributable to shareholders for 2020 was CNY 675,356,413.28, a significant increase of 233.55% from CNY 202,475,418.80 in the previous year[16] - The net cash flow from operating activities reached CNY 1,367,198,250.32, marking a 449.36% increase compared to CNY 248,872,034.68 in 2019[16] - The basic earnings per share for 2020 was CNY 1.3345, up 238.10% from CNY 0.3947 in 2019[16] - The total assets at the end of 2020 amounted to CNY 5,977,153,474.43, reflecting a 61.33% increase from CNY 3,704,842,430.09 at the end of 2019[16] - The net profit after deducting non-recurring gains and losses for 2020 was CNY 658,928,540.60, which is a 258.44% increase from CNY 183,830,664.07 in 2019[16] - The company reported a weighted average return on equity of 24.76%, an increase of 15.85 percentage points from 8.91% in 2019[16] - The revenue from self-produced products amounted to ¥2,681,480,912.21, a significant increase of 145.67% from ¥1,091,489,519.78 in the previous year[66] - The international revenue surged by 283.88%, reaching ¥851,395,974.97, compared to ¥221,789,113.38 in 2019[66] - The company reported a cash dividend of ¥102,871,448.60 for the fiscal year 2020, which represents 15.23% of the net profit attributable to ordinary shareholders[128] Market Position and Strategy - The company has a total of over 260 approved diagnostic reagents and instruments, with 80 products certified by the EU CE mark[25] - The company focuses on three main diagnostic areas: immunodiagnostics, biochemical diagnostics, and molecular diagnostics, enhancing its product portfolio[25] - The company aims to become a pillar in the IVD field, emphasizing customer-centric innovation and collaboration[25] - The company has established a network of over 12,000 terminal hospitals and more than 500 high-barrier disease control centers and blood centers across 30 provinces and regions in China[29] - The company has seen a notable increase in its share of the domestic IVD market due to the shift towards domestic products amid import substitution trends[42] - The company is positioned to benefit from national policies supporting the biotechnology industry, which is recognized as a strategic emerging industry[39] - The company aims to leverage its comprehensive advantages in the in vitro diagnostic industry to drive innovation and develop new products that meet market demands[104] Research and Development - The company has established a postdoctoral research station and several technology innovation centers, reinforcing its commitment to R&D[25] - The company has over 100 ongoing research projects and has obtained 260 CFDA registration certificates and over 50 invention patents[46] - The company has made significant investments in the R&D of intelligent medical devices, particularly in its subsidiary Xi'an Tianlong[45] - Research and development expenses rose by 123.76% to CNY 146.93 million in 2020, compared to CNY 65.66 million in 2019[76] - In 2021, the company plans to enhance its R&D capabilities by increasing investment and recruiting high-tech talent, focusing on molecular and immunological fields[106] Product Development and Innovation - The company sold over 13,500 nucleic acid extraction devices and 9.1 million nucleic acid extraction reagents during the reporting period, significantly boosting sales performance[56] - The Polaris series products, including fully automated biochemical and immunoassay systems, have been launched, with the Polaris C2000 achieving a testing speed of 2,000 tests per hour[57] - The company has developed 35 new biochemical diagnostic products, 44 new chemiluminescence products, and 23 new molecular diagnostic products, all at various stages of development[59] - The company actively developed COVID-19 testing solutions, contributing to its significant sales growth during the pandemic[56] - The company has successfully registered its AIDS diagnostic products in over 30 countries, contributing significantly to global AIDS prevention efforts[187] Corporate Governance and Compliance - The company has established a quality assurance department and a regulatory affairs department to ensure timely registration of products in domestic and international markets[116] - The company has a cash dividend policy that mandates a minimum of 10% of the distributable profit to be distributed as cash dividends, with a cumulative distribution of at least 30% over three years[123] - The company has established a comprehensive quality management system in compliance with GMP, ISO13485, and other relevant standards, ensuring rigorous quality control throughout the production process[184] - The company has maintained compliance with environmental protection laws and has not faced any significant penalties during the reporting period[190] - The company has received the AAA credit rating for contract compliance from Shanghai for several consecutive years, indicating strong financial stability and debt repayment capability[178] Social Responsibility and Community Engagement - The company actively engages in corporate social responsibility, balancing profit maximization with contributions to sustainable development and social welfare[1] - The company has actively participated in the fight against COVID-19 by donating 10,000 nucleic acid test kits to Wuhan hospitals and providing additional support to other medical institutions[188] - The company has a strong commitment to social responsibility, actively engaging in blood donation activities and supporting public health initiatives[187] Risks and Challenges - The company recognizes the ongoing risks posed by the COVID-19 pandemic, which may affect the sales of routine diagnostic products[113] - Regulatory changes in the in vitro diagnostic industry pose potential risks, necessitating close monitoring and adjustments to comply with new policies[114] - The company faces high risks in new product development due to the complex and lengthy process, which typically takes 3-5 years from project initiation to market launch[115] - The company has faced challenges in timely registration of innovative products, which could adversely affect its business plans[116] Shareholder Engagement and Financial Management - The company held 2 shareholder meetings in 2020, utilizing online voting to facilitate participation from public shareholders, especially small and medium-sized shareholders[174] - The board approved the profit distribution plan, which is subject to shareholder approval at the annual general meeting[130] - The company has not proposed any stock dividends or capital reserve transfers for the fiscal year 2020[130] - The company has not proposed any share buybacks during the reporting period[129]

上海科华生物工程股份有限公司 2021 年第一季度报告全文 上海科华生物工程股份有限公司 2021 年第一季度报告 2021 年 04 月 1 上海科华生物工程股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 1,453,210,918.22 | 536,588,796.53 | 170.82% | | 归属于上市公司股东的净利润（元） | 342,225,938.64 | 49,996,448.89 | 584.50% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 340,651,901.14 | 46,250,398.68 | 636.54% | | 经营活动产生的现金流量净额（元） | 352,209,941.61 | 55,450,002.38 | 535.18% | ...

上海科华生物工程股份有限公司 2020 年第三季度报告全文 上海科华生物工程股份有限公司 2020 年第三季度报告 2020 年 10 月 1 上海科华生物工程股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人周琴琴、主管会计工作负责人罗芳及会计机构负责人（会计主管人员）许振中声明：保证 季度报告中财务报表的真实、准确、完整。 2 上海科华生物工程股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 1、报告期经营情况概述 报告期内，公司始终围绕发展战略目标，专注主营业务，聚焦优势领域，坚定有序开展各项工作，坚 持技术创新，丰富公司产品线，优化资源配置，深化分子诊断业务的战略布局。受新冠病毒肺炎疫情影响， 疫情期间国内医院的常规门急诊就诊人数明显下降，公司传统生化免疫业务收入下降。同时，公司积极把 握因新冠病毒肺炎疫情激增的分子诊断业务市场需求，充分发挥 ...

上海科华生物工程股份有限公司 2020 年半年度报告全文 上海科华生物工程股份有限公司 2020 年半年度报告 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质性承诺，投资者及相关人士应 当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 2020 年 08 月 1 | 第一节 | 重要提示、目录和释义 | 3 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 5 | | 第三节 | 公司业务概要 | 8 | | 第四节 | 经营情况讨论与分析 11 | | | 第五节 | 重要事项 | 20 | | 第六节 | 股份变动及股东情况 | 26 | | 第七节 | 优先股相关情况 | 31 | | 第八节 | 可转换公司债券相关情况 | 32 | | 第九节 | 董事、监事、高级管理人员情况 | 33 | | 第十节 | 公司债相关情况 | 35 | | 第十一节 | 财务报告 | 36 | | 第十二节 | 备查文件目录 | 139 | 上海科华生物工程股份有限公司 2020 年半年度报告全文 第一节 ...